@Nancyhunter1984 @donaldbarnat @covidjabstroke This is May 2020 so I don't know what the follow up studies found. The misleading wiki quote you shared was based on this study. You also, predictably, misunderstand the nuanced differences between "side ef
@JamesLynchGTC @PavlosPavlova @Pickles_Malone This one had remdesevir being stopped early in a portion of the participants due to safety concerns. https://t.co/Viz3D794n2 Killing people obviously means it's harmful.
RT @rodedc1: @drcraigwax There are many studies with equivocal results using remdesivir that I have saved since the plandemic began. At fir…
@drcraigwax There are many studies with equivocal results using remdesivir that I have saved since the plandemic began. At first it was touted as another savior for those who got the C,not so much in most papers ... https://t.co/fwa17WEnQl
@Ravie777 Do you think Remdesivir was the safest way to treat COVID? https://t.co/qfagLjXL6e "More patients in the remdesivir group than the placebo group discontinued the study drug because of adverse events or serious adverse events (18 [12%] in the re
RT @HumanityWins333: In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistic…
#justdoingmyjob #hospitalprotocols #injustice #humanlifematters In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits. Another Lanset study: https://t.c
In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits. Another Lanset study: https://t.co/u2UDjOQ70W #justdoingmyjob #hospitalprotocols #injustice #hum
RT @keisuke4713: 復習 🇨🇳重度コロナremdesivir(R) :無作為化、二重盲検https://t.co/JyVXHpkaho 重症者に有意臨床効果や抗🦠効果無し R群でplacebo群より有害事象・重篤有害事象で中止18人12%対4人5% うち7人5%…
RT @filipe_rafaeli: @CogitaTuti Homero, eu aceito seu argumento de que "a ciência criou os protocolos de rigor que restringem a atuação das…
RT @filipe_rafaeli: Homeopatia, acupuntura, essas coisas não servem para nada. Mas a partir daí, você sair defendendo a indústria farmacêut…
RT @filipe_rafaeli: Homeopatia, acupuntura, essas coisas não servem para nada. Mas a partir daí, você sair defendendo a indústria farmacêut…
Homeopatia, acupuntura, essas coisas não servem para nada. Mas a partir daí, você sair defendendo a indústria farmacêutica e seu "rigor" significa um ato de ingenuidade sem limites.
@CogitaTuti Homero, eu aceito seu argumento de que "a ciência criou os protocolos de rigor que restringem a atuação das indústrias" se você justificar para mim o Remdesivir sendo recomendado em Abril de 2020 em cima desse estudo. (e virando SOC nos EUA).
Very interesting study https://t.co/IPJj08c7bP
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - The Lancet. Not particularly good results. https://t.co/vsrrPJmFP7
Het door het kabinet #Rutte van VVD, D66, @CDA, Christenunie en gedoogpartners GroenLinks en PvdA verboden medicijn #Remdesivir blijkt het verschil te zijn voor "het blijven leven met Remdesivir of dood zonder Remdesivir "! #Coronabedrog #oversterfte http
@mpc_xetts @dr_jon_l No benefits clown... https://t.co/Bit3pNQMNR
@mpc_xetts @dr_jon_l https://t.co/5jdXAKPCfr https://t.co/eYj73N0z3b https://t.co/gjGg90I7MV https://t.co/eHf1whIcI5 You are asleep you clown...
RT @dr_SDRK: FDA approves #Remdesivir in October 2020, while this Chinese trial has used Remdesivir in it’s clinical trial between Feb 6, 2…
RT @dr_SDRK: FDA approves #Remdesivir in October 2020, while this Chinese trial has used Remdesivir in it’s clinical trial between Feb 6, 2…
FDA approves #Remdesivir in October 2020, while this Chinese trial has used Remdesivir in it’s clinical trial between Feb 6, 2020, and March 12, 2020!!!! https://t.co/RLHIMMMRRg https://t.co/sS5dQhvnXP @Charles04144986 https://t.co/ReqQJfBJaM
@mpc_xetts @denise_dewald Really no statistical difference. Plus. Not safe. https://t.co/Ljz4BkKPdz
@bob68095936 @WolnoscTV @GrzegorzBraun_ @KoronyPolskiej @KONFEDERACJA_ Co do remdesiviru, masz coś bez konfliktu interesu, takiego wręcz ordynarnego? Jakieś badania nie projektowane przez producenta? Znalazłem coś co pod tym względem wygląda dużo lepiej,
@Standing4Rights @lagerth13136056 @Er_Nope @sanjay_world The WIKI page you supplied, and the section you quoted linked to THIS study. There was a 2% increase in AEs above placebo! 🤪🤣 "Adverse events were reported in 102 (66%) of 155 remdesivir recipients
@JordanA8156 @425digs @LeilaniDowding 20 fold increase in kidney damage https://t.co/djhvN2PKp7 No use against COVID https://t.co/yhXg0sNpAm
RT @bosanskakaf: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial https://t.co/…
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial https://t.co/4PIAV7U2kX «More patients in the remdesivir group than the placebo group discontinued the study drug because of adverse events or se
@trifan_tatiana Wikipedia cites a 2020 study on side effects: https://t.co/B4mnS6iGLh
@JordanA8156 @deepdiver501 @Censored4sure @Tophrrr You just refuse to accept the fact that a higher proportion of people died in the remdesivir group than the control group. How about this study? I can send you more, if you’d like… https://t.co/BI6eZCXNKe
@Tophrrr There was no clinical benefits to using remnesivir so why did that use it knowing it could cause kidney failure. https://t.co/GyOZZuDcJD
RT @LukeMor19529310: 7/ Then we found out that Fauci rushed his announcement, because someone released another study to the Lancet, showing…
RT @LukeMor19529310: 7/ Then we found out that Fauci rushed his announcement, because someone released another study to the Lancet, showing…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
Please share with your lawmakers, or if appropriate, your lawyer!
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
“Run-Death-Is-Near”
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
Yet another damning example of harm to patients.
RT @kacdnp91: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https:/…
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial - PubMed https://t.co/6PHPVNqUJN
RT @keisuke4713: 復習 🇨🇳重度コロナremdesivir(R) :無作為化、二重盲検https://t.co/JyVXHpkaho 重症者に有意臨床効果や抗🦠効果無し R群でplacebo群より有害事象・重篤有害事象で中止18人12%対4人5% うち7人5%…
https://t.co/8krN1Tis5o is link to the actual study.
RT @keisuke4713: 復習 🇨🇳重度コロナremdesivir(R) :無作為化、二重盲検https://t.co/JyVXHpkaho 重症者に有意臨床効果や抗🦠効果無し R群でplacebo群より有害事象・重篤有害事象で中止18人12%対4人5% うち7人5%…
復習 🇨🇳重度コロナremdesivir(R) :無作為化、二重盲検https://t.co/JyVXHpkaho 重症者に有意臨床効果や抗🦠効果無し R群でplacebo群より有害事象・重篤有害事象で中止18人12%対4人5% うち7人5%はR群の呼吸不全かARDS 一部に複数有害事象 36人が薬物中止 うち22人有害事象で、退院や早期🙏等14人 https://t.co/N8xoULfhWd
RT @3Filary: @rieske_piotr @StabrawaL Proszę mi nie zarzucać manipulacji Panie Profesorze a skupić się na faktach. Remdesivir nie ma wpływu…
@dr_jon_l @SeaTeaShaw So did you check EUA study for remdesivir , what is endpoint that was used for approval? What is mortality ratio in the same study? https://t.co/gYYIenHfbY Comment please
@ZoranPrimorac1 @nbakic Ovo je primjeceno cak u EUA studiji koja je koristena za odobrenje, relativna smtrnost je bila veca za 8% https://t.co/gYYIenHN1w
@HectorRossete https://t.co/J9MoWQcZyF "remdesivir no esta asociado con beneficios clinicos estadisticamente significativos" se derrumbo la narrativa covid y ahora tienes que trabajar horas extras, se te cayo la productividad, tus patrocinadores no esta
@ThatWitchUKnow @ReOpenChris No, it is called "Science." https://t.co/6yFdA00q0U
@ThatWitchUKnow @ReOpenChris Remdesivir was stopped early because of adverse events in 18 (12%) https://t.co/6yFdA00q0U
here's a thread on original Remdesivir study that I did in April 2020. https://t.co/pyfZNLijh8 I think that I can fairly claim to have been skeptical of Fauci almost immediately. Long before most current Fauci skeptics.
@Project_Veritas This is NOT a scientific paper. Any such paper would have referred to prior articles such as those two - which indicated lack of both safety & effectiveness. This was before Emergency Use Authorization. But who cared at the time? https
RT @sanchak74: It is important to see the exact date of Fauci's statement and the day China said the trial failed 29th April, 2020 Imagin…
RT @sanchak74: It is important to see the exact date of Fauci's statement and the day China said the trial failed 29th April, 2020 Imagin…
It is important to see the exact date of Fauci's statement and the day China said the trial failed 29th April, 2020 Imagine the number of lives you would have saved if you had listened to the right source https://t.co/WVpfKTYoXj https://t.co/2gCDUxhm3W
For example, it hadnt registered that China had 2 failed trials ... I just knew about one "remdesivir was not associated with statistically significant clinical benefits." https://t.co/kuP1WCeRJA
Look at the date!